Magnetic stimulation reduces involuntary jerks
- Trial ID
- NCT06570824
- Official Title
- Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)
- Goal
- Magnetic stimulation reduces involuntary jerks
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Danish Research Centre for Magnetic Resonance
- Study Type
- INTERVENTIONAL
- Enrollment
- 68 participants
- Conditions
- Dyskinesia, Drug-Induced, Parkinson Disease
- Interventions
- active TMS, sham TMS
Summary For Families
They're testing whether targeted magnetic stimulation can reduce the involuntary jerks and writhing that happen at levodopa's peak, the peak-of-dose dyskinesia that many people with Parkinson's find disabling. The approach uses network-based repetitive transcranial magnetic stimulation, delivering brief magnetic pulses to modulate overactive brain circuits that drive dyskinesia, comparing active versus sham stimulation; it does not change your levodopa but aims to dampen the abnormal motor signals. The trial seeks people aged 18 to 80 with clinically established or probable Parkinson's who have peak-of-dose dyskinesia and have been on stable Parkinson medications for at least four weeks. People with epilepsy or seizure risk, certain psychiatric conditions, regular benzodiazepine or opioid use, use of antipsychotics, Donepezil or GABAergic drugs, MRI contraindications, or women who are pregnant or not using contraception are excluded, and participants must consent to be informed about any incidental health findings.
Locations
- DRCMR, Hvidovre, Denmark
Frequently Asked Questions
- What is this trial testing?
- This trial is studying active TMS. They're testing whether targeted magnetic stimulation can reduce the involuntary jerks and writhing that happen at levodopa's peak, the peak-of-dose dyskinesia that many people with Parkinson's find disabling. The approach uses network-based repetitive transcranial magnetic stimulation, delivering brief magnetic pulses to modulate overactive brain circuits that drive dyskinesia, comparing active versus sham stimulation; it does not change your levodopa but aims to dampen the abnormal motor signals. The trial seeks people aged 18 to 80 with clinically established or probable Parkinson's who have peak-of-dose dyskinesia and have been on stable Parkinson medications for at least four weeks. People with epilepsy or seizure risk, certain psychiatric conditions, regular benzodiazepine or opioid use, use of antipsychotics, Donepezil or GABAergic drugs, MRI contraindications, or women who are pregnant or not using contraception are excluded, and participants must consent to be informed about any incidental health findings.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 9 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.